Takeda Pharmaceutical Co Ltd ADR is a drug manufacturers - specialty & generic business based in the US. Takeda Pharmaceutical Co Ltd ADR shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $13.29 – a decrease of 2.06% over the previous week. Takeda Pharmaceutical Co Ltd ADR employs 49,281 staff and has a trailing 12-month revenue of around $4.5 trillion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $13.29 |
|---|---|
| 52-week range | $12.29 - $14.73 |
| 50-day moving average | $14.27 |
| 200-day moving average | $13.91 |
| Wall St. target price | $2,460.80 |
| PE ratio | 23 |
| Dividend yield | $192 (4.31%) |
| Earnings per share (TTM) | $0.59 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.62 from 2024-11-19
| 1 week (2024-11-13) | 0.44% |
|---|---|
| 1 month (2024-10-18) | -4.95% |
| 3 months (2024-08-20) | -7.72% |
| 6 months (2024-05-20) | 2.56% |
| 1 year (2023-11-20) | -2.78% |
|---|---|
| 2 years (2022-11-18) | 4.94% |
| 3 years (2021-11-19) | 10.57% |
| 5 years (2019-11-20) | 16.4911 |
Valuing Takeda Pharmaceutical Co Ltd ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical Co Ltd ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical Co Ltd ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Takeda Pharmaceutical Co Ltd ADR shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Takeda Pharmaceutical Co Ltd ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7103. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical Co Ltd ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Takeda Pharmaceutical Co Ltd ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1,328.6 billion.
The EBITDA is a measure of a Takeda Pharmaceutical Co Ltd ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4,546.1 billion |
|---|---|
| Operating margin TTM | 20.54% |
| Gross profit TTM | $2,441.7 billion |
| Return on assets TTM | 2.78% |
| Return on equity TTM | 4.15% |
| Profit margin | 6.38% |
| Book value | $4,365.91 |
| Market Capitalization | $43 billion |
TTM: trailing 12 months
Dividend payout ratio: 1% of net profits
Recently Takeda Pharmaceutical Co Ltd ADR has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical Co Ltd ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical Co Ltd ADR's case, that would currently equate to about $192 per share.
While Takeda Pharmaceutical Co Ltd ADR's payout ratio might seem low, this can signify that Takeda Pharmaceutical Co Ltd ADR is investing more in its future growth.
Takeda Pharmaceutical Co Ltd ADR's most recent dividend payout was on 7 July 2024. The latest dividend was paid out to all shareholders who bought their shares by 26 March 2024 (the "ex-dividend date").
Over the last 12 months, Takeda Pharmaceutical Co Ltd ADR's shares have ranged in value from as little as $12.287 up to $14.7347. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical Co Ltd ADR's is 0.464. This would suggest that Takeda Pharmaceutical Co Ltd ADR's shares are less volatile than average (for this exchange).
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc. , Seagen Inc. , Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc. , Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.